Single ocular injection of a sustained-release anti-VEGF delivers 6months pharmacokinetics and efficacy in a primate laser CNV model.

A potent anti-vascular endothelial growth factor (VEGF) biologic and a compatible delivery system were co-evaluated for protection against wet age-related macular degeneration (AMD) over a 6month period following a single intravitreal (IVT) injection. The anti-VEGF molecule is dimeric, containing two different anti-VEGF domain antibodies (dAb) attached to a human IgG1 Fc region: a dual dAb. The delivery system is based on microparticles of PolyActive™ hydrogel co-polymer.

[Neonatal seizures: consider sinus thrombosis].

Cerebral sinovenous thrombosis is a possible cause of neonatal seizures. It can be demonstrated by neuroradiological Doppler ultrasound or MRI/MRV. Maternal, perinatal and neonatal factors all contribute to the development of sinovenous thrombosis.

Characterization and simulation of optical sensors.

Numerical simulation is gradually becoming an advantage in active safety. This is why the development of realistic numerical models enabling to substitute real truth by simulated truth is primordial. In order to provide an accurate and cost effective solution to simulate real optical sensor behavior, the software Pro-SiVIC™ has been developed.

Probable association of tachyarrhythmia with nebulized albuterol in a child with previously subclinical wolff Parkinson white syndrome.

We present the case of a 2-year-old asthmatic boy with atrioventricular (AV)-reentry tachycardia following albuterol inhalation, who was later diagnosed with Wolff-Parkinson-White (WPW) syndrome. The Naranjo adverse drug reaction probability scale score for this adverse event was 7, indicating that the association between his AV-reentry tachycardia and inhalation of albuterol is probable. To our knowledge, this is the first case report that shows the potential arrhythmogenic effects of albuterol in a child with WPW syndrome.